Skip to content

The Health After Cancer podcast brings together Stanford Medicine physicians, cancer survivors and advocates to discuss issues around cancer survivorship and health after cancer treatment.

The Health After Cancer podcast brings together Stanford Medicine physicians, cancer survivors and advocates to discuss issues around cancer survivorship and health after cancer treatment.

Published on

Stanford Medicine brain cancer researchers joined other thought leaders in Washington, D.C. to discuss what the Biden Administration-led Cancer Moonshot initiative could mean.

Stanford Medicine brain cancer researchers joined other thought leaders in Washington, D.C. to discuss what the Biden Administration-led Cancer Moonshot initiative could mean.

Published on

Neurosurgeon Michael Lim studies how to unleash the immune system to attack a type of brain cancer called glioblastoma.

Neurosurgeon Michael Lim studies how to unleash the immune system to attack a type of brain cancer called glioblastoma.

Published on

A common ovarian cancer evades detection by convincing nearby immune cells to treat it as a developing fetus.

A common ovarian cancer evades detection by convincing nearby immune cells to treat it as a developing fetus.

Published on

A team led by Howard Chang has contributed key technology to enable new experimental cancer therapy that uses CRISPR to edit immune cells.

A team led by Howard Chang has contributed key technology to enable new experimental cancer therapy that uses CRISPR to edit immune cells.

Screening more than 9,000 pairs of drugs helped Stanford and NIH scientists identify two drugs that synergize against a deadly childhood brain tumor.

Screening more than 9,000 pairs of drugs helped Stanford and NIH scientists identify two drugs that synergize against a deadly childhood brain tumor.

Published on

Pioneering immunotherapy drug Provenge is enjoying a revival, thanks to a large new clinical trial that will test it in men with early prostate cancer.

Pioneering immunotherapy drug Provenge is enjoying a revival, thanks to a large new clinical trial that will test it in men with early prostate cancer.

Stanford scientists have moved a big step closer toward using engineered immune cells to treat many forms of pediatric cancer.

Stanford scientists have moved a big step closer toward using engineered immune cells to treat many forms of pediatric cancer.

Published on

Sharon Chinthrajah weighs in on a new peanut allergy immunotherapy, speaking to its potential and its role in the future of food allergies therapy.

Sharon Chinthrajah weighs in on a new peanut allergy immunotherapy, speaking to its potential and its role in the future of food allergies therapy.